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Abstract  
Introduction: Posterior Reversible 
Leukoencephalopathy Syndrome (PRES) is caused by 
ischaemia commonly affecting the posterior cerebral 
vasculature. It presents with sudden decreased vision, 
headaches, nausea, vomiting, seizures, and altered 
mental status.    
Case presentation: A 19-year-old male presented to 
the ophthalmic emergency complaining of sudden 
bilateral loss of vision, which was down to light 
perception He reported headaches, nausea, and 
drowsiness since the previous day. He was a known case 
of hypertension secondary to IgA nephropathy. 
Magnetic resonance imaging (MRI) with STIR and 
FLAIR sequences showed foci of hyperintensity within 
the occipital lobes bilaterally. This confirmed the 
suspected diagnosis of PRES.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion: Aetiological factors of PRES include 
sudden increase in blood pressure, eclampsia, porphyria, 
renal disease, and Cushing syndrome. These lead to 
blood-brain barrier injury either by hyper- or hypo-
perfusion, endothelial dysfunction, changes in blood 
vessel morphology, hypocapnea, or immune system 
activation. Histopathological changes in PRES include 
activated astrocytes, scattered macrophages and 
lymphocytes, often in the absence of inflammation or 
neuronal damage.  
Conclusion: PRES is usually a reversible neuro-
ophthalmological condition, however prompt 
recognition and appropriate management is important to 
prevent permanent brain injury or even death. 
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Introduction 
Posterior reversible encephalopathy syndrome was 
first described by Hinchey et al 1 in 1996. It is caused by 
ischaemia, usually due to a sudden increase in blood 
pressure commonly affecting the posterior cerebral 
vasculature. It presents with headaches, nausea, 
vomiting, decreased vision, seizures, and altered mental 
status. Other causes of PRES include eclampsia, 
porphyria, renal disease, Cushing syndrome and 
adrenocortical disease, as well as immunosuppressive or 
cytotoxic drugs.1-2  
To explain the pathophysiology of hypertensive 
PRES two theories have been proposed: 1) Severe 
hypertension leading to failed auto-regulation with 
subsequent hyperperfusion and endothelial injury 
causing vasogenic oedema;  2) vasoconstriction and 
hypoperfusion leading to brain ischaemia and 
consequent vasogenic oedema. Non-hypertensive PRES 
may be due to an immune response to endogenous or 
exogenous stimuli.3 
PRES is usually a reversible condition, however 
prompt recognition and appropriate management is 
important to prevent permanent brain injury or even 
death. 
In this paper we present a case of a young 
gentleman with IgA nephropathy who presented with 
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sudden, severe, bilateral loss of vision due to PRES. 
 
Case Presentation 
In January 2012 a 19-year-old Caucasian male 
presented to the ophthalmic emergency with sudden 
bilateral loss of vision down to light perception 
associated with headaches, nausea, and drowsiness since 
the previous day. He had been diagnosed with 
hypertension secondary to IgA nephropathy at the age of 
16 years and was on perindopril 8mg nocte. An 
ophthalmological assessment did not reveal any 
abnormality, with normal pupillary reflexes to light and 
no fundal pathology. On examination he was agitated 
but had no focal neurological signs and a GCS of 15.  
His blood pressure was 230/140mmHg, pulse rate was 
95bpm, and body temperature was 37˚C. He was 
referred to the main A&E department for urgent 
medical/neurological review and further management. 
Neurological examination showed normal power in all 
four limbs, normal sensation, no neck stiffness, and 
down-going plantar reflexes. His GCS began to 
deteriorate and he suffered two episodes of witnessed 
seizures in the casualty department. Complete blood 
count, liver function tests, erythrocyte sedimentation 
rate, C-reactive protein and coagulation screen were all 
normal.  His serum creatinine was 328µmol/l and serum 
potassium 6. A CT scan of the brain revealed 
hypodensities in both occipital lobes (Figure 1).  
 
Figure 1: PRES - Initial axial CT showing occipital 
hypodensity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 MRI with STIR and FLAIR sequences showed foci 
of hyperintensity within the occipital lobes bilaterally 
(Figure 2). The rest of the brain was normal.  
The patient was admitted to the intensive therapy 
unit and was started on intravenous labetolol and 
phenytoin. In order to control his hypertension he was 
gradually started on calcium channel blockers, 
angiotensin receptor blockers, and alpha-agonists. An 
echocardiogram showed concentric left ventricular 
hypertrophy and no regional wall motion abnormality. 
He also required haemodialysis on several occasions to 
control his renal failure. Repeat MRI one month later 
showed complete resolution of the vasogenic brain 
oedema (Figure 3). This confirmed the suspected 
diagnosis of PRES.  The patient spent 37 days in the 
intensive therapy unit and was fit for discharge two 
months after admission. 
 
Figure 2: PRES - Axial view MRI FLAIR showing 
occipital hyperintensity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: PRES - Axial view MRI FLAIR after 1 month 
showing resolution of previous changes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
The differential diagnoses that have to be 
considered when a patient presents with confusion, 
headaches, nausea, and/or vomiting, associated with 
blurred vision include: PRES, cerebrovascular accidents, 
intracranial haemorrhage, space-occupying lesions, 
raised intracranial pressure (idiopathic or secondary to 
other pathology), hypertensive encephalopathy,  
meningitis, encephalitis, and migraine. 
PRES is a neurotoxic state which results in a unique 
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brain imaging appearance. The basic PRES pattern 
shows changes in the cortex, with subcortical and deep 
white matter involved to varying degrees.4-8 
Various aetiological factors have been implicated in 
the pathophysiology of PRES. These lead to blood-brain 
barrier injury either by hyper- or hypo-perfusion, 
endothelial dysfunction, changes in blood vessel 
morphology, hypocapnea, or immune system 
activation.3,9-10  
In hypertension-induced PRES, there is failure of 
cerebral autoregulation which predominantly affects the 
vertebrobasilar system, probably due to sparse 
sympathetic innervation of the posterior circulation. As a 
result, the parietal and occipital lobes are most 
commonly affected.11-12 
PRES is also associated with sepsis, usually due to 
Gram-positive organisms. In these patients blood 
pressure is often normal or only minimally increased. On 
imaging, vasogenic oedema is greater in normotensive 
patients than in severely hypertensive ones.13 
The autoimmune diseases that have been associated 
with PRES include systemic lupus erythematosus, 
Wegener’s granulomatosis, systemic sclerosis, and 
polyarteritis nodosa. These patients are usually managed 
with intermittent courses of immunosuppressants to keep 
the disease under control.14-19 
PRES is also recognized in patients undergoing 
bone marrow or stem cell transplants, especially when 
high-dose myeloablative regimens are applied.20-26 It 
usually occurs in the first month after allogeneic  bone 
marrow transplantation, with the rest occurring in the 
subsequent year.20,24,26-27 Several PRES-related risks co-
exist in post-transplant patients. Immunosuppressive 
drugs, such as cyclosporine, can induce endothelial 
injury that leads to vasoconstrictive effects, increased 
sympathetic activation, and coagulation abnormalities.28-
33 Effects of chemotherapy and infection in 
immunosuppressed patients further contribute to 
toxicity. 
PRES has also been strongly associated with 
toxaemia of pregnancy.34-39 Although blood pressure is 
high in the majority of cases, it has also been reported to 
be normal in others.40-41 
Histopathological changes in PRES include 
activated astrocytes, scattered macrophages and 
lymphocytes, often in the absence of inflammation, 
ischaemia or neuronal damage. Demyelination, neuronal 
anoxic damage, laminar necrosis and old haemorrhage in 
the white matter and cortex have also been shown to 
occur on autopsy.20,42 
MRI is the gold standard imaging modality to 
diagnose PRES. The commonest findings on MRI are 
focal areas of vasogenic oedema in the white matter of 
the posterior cerebral hemispheres. These changes are 
usually in a watershed distribution.4-8 The medial part of 
the occipital lobe is not affected in PRES, therefore 
differentiating it from bilateral posterior cerebral artery 
infarcts.43 The aetiological factor of PRES does not seem 
to affect the radiological appearance. 44 
In hypertension-induced PRES, repeat MRI after 
blood pressure control usually shows improvement or 
complete resolution of the radiological findings.   
 
Conclusion 
The pathophysiology of PRES is not completely 
understood. Hypertension with failed autoregulation and 
hyperperfusion is the primary theory for the mechanism 
of brain oedema.21,45-47 Other mechanisms proposed 
include endothelial dysfunction, hypoperfusion, and 
vasoconstriction which compromise the blood-brain 
barrier. 48-49 
The controversies with the hypertension-
hyperperfusion theory are highlighted by the absence of 
hypertension in 20-40% of patients.8,13,42 And in mild 
hypertension, the blood pressure does not typically reach 
the limit of autoregulation.50 
The outcome of this condition depends on timely 
diagnosis and prompt management. Treating the 
underlying cause is usually enough to reverse the 
condition. However, if the brain insult is prolonged, 
irreversible infarction can occur. Cerebral damage is 
augmented if haemorrhage and raised intracranial 
pressure ensue. 51 
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